BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3025504)

  • 1. Epidemiology of borderline ovarian tumors.
    Harlow BL; Weiss NS; Lofton S
    J Natl Cancer Inst; 1987 Jan; 78(1):71-4. PubMed ID: 3025504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
    Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
    Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary.
    Malkasian GD; Melton LJ; O'Brien PC; Greene MH
    Am J Obstet Gynecol; 1984 Jun; 149(3):274-84. PubMed ID: 6328995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
    Giurgea NL; Pitrop M; Mihailovici MS
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.
    Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
    Lee KR; Castrillon DH; Nucci MR
    Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.
    Yoshida A; Sarian LO; Andrade LA; Pignataro F; Pinto GA; Derchain SF
    Int J Gynecol Cancer; 2007; 17(3):607-14. PubMed ID: 17504375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current issues in the pathology of ovarian cancer.
    Rabban JT; Bell DA
    J Reprod Med; 2005 Jun; 50(6):467-74. PubMed ID: 16050571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
    Litkouhi B; Litkouhi B; Fleming E; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
    Gynecol Oncol; 2008 May; 109(2):234-9. PubMed ID: 18331757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic sampling requirements in ovarian carcinoma: a review of 51 tumors.
    Gramlich T; Austin RM; Lutz M
    Gynecol Oncol; 1990 Aug; 38(2):249-56. PubMed ID: 2167283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history.
    Hazard FK; Longacre TA
    Am J Surg Pathol; 2013 Apr; 37(4):548-53. PubMed ID: 23388124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential).
    Scully RE
    Bull Cancer; 1982; 69(3):228-38. PubMed ID: 6289947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of the intestinal type.
    Miller K; Millar J; McCluggage WG
    Am J Surg Pathol; 2011 Sep; 35(9):1331-6. PubMed ID: 21836488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic parameters in patients with advanced ovarian malignant tumors.
    Pohl R; Dallenbach-Hellweg G; Plügge T; Czernobilsky B
    Eur J Gynaecol Oncol; 1984; 5(3):160-9. PubMed ID: 6329760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.